NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 312 filers reported holding NOVOCURE LTD in Q4 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,612,202 | -70.3% | 87,041 | -57.0% | 0.02% | -72.7% |
| Q1 2023 | $12,169,869 | -17.2% | 202,359 | +1.0% | 0.06% | -23.6% |
| Q4 2022 | $14,701,541 | +143.2% | 200,430 | +151.9% | 0.07% | +105.7% |
| Q3 2022 | $6,045,000 | -20.3% | 79,559 | -27.1% | 0.04% | -12.5% |
| Q2 2022 | $7,581,000 | +244.6% | 109,075 | +310.8% | 0.04% | +263.6% |
| Q1 2022 | $2,200,000 | -3.9% | 26,551 | -12.9% | 0.01% | +10.0% |
| Q4 2021 | $2,289,000 | -37.0% | 30,482 | -2.6% | 0.01% | -37.5% |
| Q3 2021 | $3,634,000 | -57.8% | 31,284 | -19.4% | 0.02% | -57.9% |
| Q2 2021 | $8,613,000 | +49.2% | 38,830 | -11.1% | 0.04% | +35.7% |
| Q1 2021 | $5,773,000 | +142.8% | 43,672 | +217.8% | 0.03% | +133.3% |
| Q4 2020 | $2,378,000 | -2.4% | 13,742 | -37.2% | 0.01% | -14.3% |
| Q3 2020 | $2,437,000 | +3.8% | 21,896 | -44.7% | 0.01% | -6.7% |
| Q2 2020 | $2,347,000 | -35.5% | 39,581 | -26.8% | 0.02% | -44.4% |
| Q1 2020 | $3,640,000 | – | 54,057 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |